A reappraisal of the mucoactive activity and clinical efficacy of bromhexine

Alessandro Zanasi, Massimiliano Mazzolini, Ahmad Kantar, Alessandro Zanasi, Massimiliano Mazzolini, Ahmad Kantar

Abstract

Since its introduction to the market in 1963, bromhexine, an over-the-counter drug, has been investigated for its activity in animal models and in humans with diverse respiratory conditions. Bromhexine is a derivate of the Adhatoda vasica plant used in some countries for the treatment of various respiratory diseases. Bromhexine has been found to enhance the secretion of various mucus components by modifying the physicochemical characteristics of mucus. These changes, in turn, increase mucociliary clearance and reduce cough. Principal clinical research studies were primarily developed in an era when stringent methodological approaches and good clinical practices were not developed yet. Clinical studies were conducted mainly in patients with chronic bronchitis and in patients with various respiratory diseases, and demonstrated the efficacy of bromhexine in improving respiratory symptoms. Furthermore, the co-administration of antibiotics with bromhexine amplified the actions of the antibiotic. Although the clinical evidence shows only modest but positive results, bromhexine is indicated for its mucoactive activity. Larger trials with adequate methodology are required to identify when treatment with bromhexine can improve clinical outcomes.

Keywords: Bromhexine; Bronchitis; Chronic; Cough; Expectorants [Pharmacological Action]; Pediatrics.

References

    1. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Eng J Med. 2010;363:2233–2247. doi: 10.1056/NEJMra0910061.
    1. Clarke SW, Pavia D. Lung mucus production and mucociliary clearance: methods of assessment. Br J Pharmac. 1980;9:537–546. doi: 10.1111/j.1365-2125.1980.tb01078.x.
    1. Williams OW, Sharafkhaneh A, Kim V, Dickey BF, Evans CM. Airway mucus: from production to secretion. Am J Respir Cell Mol Biol. 2006;34:527–36.
    1. Richardson PS, Phipps RJ. The anatomy, physiology, pharmacology and pathology of tracheobronchial mucus secretion and the use of expectorant drugs in human disease. Pharmacol Ther B. 1978;3:441–479.
    1. Rubin BK. Pharmacologic management of mucus retention based on taxonomy of mucoactive medications. In: Baum GL, Priel Z, Roth V, Liron N, Ostfeld EJ, editors. Cilia, mucus and mucociliary interactions. New York: Marcel Drekker; 1998. pp. 383–9.
    1. Dhankhar S, Kaur R, Ruhil S, Balhara M, Dhankhar S, Chhillar AK. A review on Justicia adhatoda: a potential source of natural medicine. Afr J Plant Sci. 2011;5:620–627.
    1. Amin AH, Mehta DR. A bronchodilator alkaloid (vasicinone) from Adhatoda vasica Nees. Nature. 1959;184:1317. doi: 10.1038/1841317a0.
    1. Merker HJ. Elektronenmikroskopische Untersuchungen über die Wirkung von N-Cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)-ammoniumchlorid auf das Bronchialepithel der Ratte. Arzneim Forsch (Drug Res) 1966;16:509–516.
    1. Gieseking R, Baldamus U. Elektronenmikroskopische befunde an der menschlichen bronchialschleimhaut nach behandlung mit Bisolvon. Beitr Klin Tuberk. 1968;137:1–18. doi: 10.1007/BF02091445.
    1. Janatuinen M, Korhonen LK. The effect of a substituted benzylamine (Bisolvon®) on mucosubstance production. Naunyn Schmiedebergs Arch Pharmakol. 1969;265:112–117. doi: 10.1007/BF00997144.
    1. Gil J, Thurnheer U. Morphometric evaluation of ultrastructural changes in type II alveolar cells of rat lung produced by bromhexine. Respiration. 1971;28:438–456. doi: 10.1159/000192830.
    1. Harada Y, Sasaki H, Gaafar H. The effect of an expectorant on tracheal mucosa. A scanning-electron microscopic study. ORL. 1977;39:113–121. doi: 10.1159/000275343.
    1. Lorenz U, Rüttgers H, Fux G, Kubli F. Fetal pulmonary surfactant induction by bromhexine metabolite VIII. Am J Obstet Gynec. 1974;119:1126–8.
    1. Von Wichert P, Bavendamm U, Von Teichmann M, Müller G, Thalheim E, Wilke A, et al. Increased incorporation of fatty acids into phospholipids of lungs and livers of rabbits under the influence of bromhexine and ambroxol. Naunyn Schmiedebergs Arch Pharmacol. 1977;297:269–73. doi: 10.1007/BF00509271.
    1. Crimi P, Zupo S, Mantellini E, Mereu C, Crimi E, Vignolo C, et al. The effect of bromhexine on phospholipid concentration in bronchial and bronchoalveolar lavage. Pan Med. 1986;28:303–5.
    1. Pamplona R. Membrane phospholipids, lipoxidative damage and molecular integrity: a causal role in aging and longevity. Biochim Biophys Acta. 2008;1777:1249–1262. doi: 10.1016/j.bbabio.2008.07.003.
    1. Centanni S, Santus P, Di Marco F, Fumagalli F, Zarini S, Sala A. The potential role of tocopherol in asthmaand allergies: modification of the leukotriene pathway. BioDrugs. 2001;15:81–6. doi: 10.2165/00063030-200115020-00002.
    1. Flavell Matts SG, Zorbala-Mallios H, Southgate J. Sputum fibre systems in exacerbations of longstanding pulmonary disease. A comparison of antibiotics and bromhexine (Bisolvan) Clin Trials J. 1973;10:75–80.
    1. Bürgi H. Changes in the fibre system and viscosity of the sputum of bronchitis during treatment with bromhexine and guaiphenesin (Guaiacol Glyceryl Ether) Scand J Res Dis. 1974;90(S):81–85.
    1. Shimura S, Okubo T, Maeda S, Aoki T, Tomioka M, Shindo Y, et al. Effect of expectorants on relaxation behavior of sputum viscoelasticity in vivo. Biorheology. 1983;20:677–83.
    1. Langlands JHM. Double-blind clinical trial of bromhexine as a mucolytic drug in chronic bronchitis. Lancet. 1970;295:448–450. doi: 10.1016/S0140-6736(70)90835-4.
    1. Stark E. A controlled trial of the effects of bromhexine on the symptoms of out-patients with chronic bronchitis. Br J Dis Chest. 1973;67:49–60. doi: 10.1016/0007-0971(73)90007-7.
    1. Götz H, Fischer M. Verhalten der elektrophoretisch, biochemisch und immunologisch definierbaren proteine des sputums unter sekretolyse. Clin Chim Acta. 1970;30:53–64. doi: 10.1016/0009-8981(70)90192-0.
    1. Kado M. Local immunity in respiratory organs: immunoglobulin and lysozyme in bronchial washings. Jap J Chest Dis. 1976;35:893.
    1. Thomson ML, Pavia D, Gregg I, Stark JE. Bromhexine and mucociliary clearance in chronic bronchitis. Brit J Dis Chest. 1974;68:21–27. doi: 10.1016/0007-0971(74)90004-7.
    1. Pavia D, Clarke SW, Thomson ML. Effect of mucolytic and expectorant agents on tracheobronchial cleranace in chronic bronchitis. Am Rev Respir Dis. 1979;119:57.
    1. Martin GP, Loveday BE, Marriott C. Bromhexine plus oxytetracycline: the effect of combined administration upon the rheological properties of mucus from the mini-pig. J Pharm Pharmacol. 1993;45:126–130. doi: 10.1111/j.2042-7158.1993.tb03696.x.
    1. Bergogne-Berezin E, Pierre J, Dournovo P. Effect of mucolytic agent (Bromhexine) on the passage of erythromycin into the bronchial secretions. Therapie. 1979;34:705–711.
    1. Roa CC, Jr, Dantes RB. Clinical effectiveness of a combination of bromhexine and amoxicillin in lower respiratory tract infection. A randomised controlled trial. Arzneimittelforschung. 1995;45:267–272.
    1. Lal S, Bhalla KK. A controlled trial of bromhexine (‘Bisolvon’) in out-patients with chronic bronchitis. Curr Med Res Opin. 1975;3:63–67. doi: 10.1185/03007997509113648.
    1. Iaia E, Marenco G. Efficacy and tolerability of a new bromhexine granulate formulation versus sobrerol granulate in patients with chronic obstructive bronchopneumopathies. Med Torac. 1990;12:215–218.
    1. Nesswetha W. Criteria of drug testing in industrial practice, demonstrated by a cough remedy. Arzneimittelforschung. 1967;17:1324–1326.
    1. Gent M, Knowlson PA, Rime FJ. Effect of bromhexine on ventilatory capacity in patients with a variety of chest diseases. Lancet. 1969;2(7630):1094–1096. doi: 10.1016/S0140-6736(69)90702-8.
    1. Hamilton WF, Palmer KNV, Gent M. Expectorant action of bromhexine in chronic obstructive bronchitis. Br Med J. 1970;3(5715):260–261. doi: 10.1136/bmj.3.5717.260.
    1. Christensen F, Kjer J, Ryskjaer S, Arseth-Hansen P. Bromhexine in chronic bronchitis. Br Med J. 1970;4(5727):117. doi: 10.1136/bmj.4.5727.117-a.
    1. Condie R. An assessment in general practice of bromhexine in the treatment of chronic bronchitis. Practitioner. 1971;207:672–676.
    1. Matts SG. A comparative trial of bromhexine HCl and oxytetracycline in acute and chronic bronchitis. Br J Clin Pract. 1974;28:403–405.
    1. Armstrong ML. Double-blind crossover trial of bromhexine (Bisolvon) in the treatment of chronic bronchitis. Med J Aust. 1976;1:612,614–615, 617.
    1. Valenti S, Marenco G. Italian multicenter study on the treatment of chronic obstructive lung disease with bromhexine. A double-blind placebo-controlled trial. Respiration. 1989;56:11–15. doi: 10.1159/000195772.
    1. Bienvenido D, Alora MD. Amoxycillin-bromhexine in the management of bronchial infection. Phil J Intern Med. 1990;28:227–233.
    1. Olivieri D, Ciaccia A, Marangio E, Marsico S, Todisco T, Del Vita M. Role of bromhexine in exacerbations of bronchiectasis. Double-blind randomized multicenter study versus placebo. Respiration. 1991;58:117–121. doi: 10.1159/000195910.
    1. Aylward M. A between-patient, double-blind comparison of S-carboxymethylcysteine and bromhexine in chronic obstructive bronchitis. Curr Med Res Opin. 1973;1:219–227. doi: 10.1185/03007997309111671.
    1. Barth A, Hovhannisyan A, Jamalyan K, Narimanyan M. Antitussive effect of a fixed combination of Justicia adhatoda, Echinacea purpurea and Eleutherococcus senticosus extracts in patients with acute upper respiratory tract infection: a comparative, randomized, double-blind, placebo-controlled study. Phytomedicine. 2015;22:1195–1200. doi: 10.1016/j.phymed.2015.10.001.
    1. Tarantino A, Stura M, Marenco G, Leproux GB, Cremonesi G. Advantages of treatment with bromexime in acute infant sinus. Min Ped. 1988;40:649–652.
    1. Molina L. Use of Na-274 in bronchopneumonia in infants. Med Klin. 1970;104:63–66.
    1. Fernandes JCM. The value of expectorant-secretolytic therapy with bromhexine in paediatrics. A Folha Medica. 1973;67:907–910.
    1. Brezina Z, Stachovà H. Bisolvan in the treatmen of bronchitis in children. Stud Pneumol Phtiseol Cechoslov. 1973;33:632–634.
    1. Okamoto K, Shino K, Ozaki H, Murakami Y, Sakai Results of administration of bisolvan fine granules for respiratory diseases in children. New Drugs Clin Med. 1981;30:2127–2132.
    1. Koga M, Saito Y. Clinical trial of bisolvon fine granules on children’s respiratory conditions. New Drugs Clin Med. 1981;30:1269–1276.
    1. Camurri S, Marenco G. Clinical evaluration of the efficacy and tolerability of the new pharmaceutical formulation bromhexine granules compared with N-acetylcysteine granules in children with acute bronchitis. Gaza Med Ital. 1990;149:45–48.
    1. Azzollini E, Bosi M, Mantegazza M, Piceci E, Careddu P. Sobrerol (sobrepin®) administered dropwise to children with acute hypersecretory bronchopulmonary disease. Clin Trails J. 1990;27:241–249.
    1. Boner AL, Antolini I, Valletta EA, Andreoli A, Mengoni M. Treatment of upper and lower respiratory tract infections in children by a combination of cephalexin plus bromhexine: a report of 100 cases. Drugs Exp Clin Res. 1984;10:455–458.
    1. Rubin BK. Surface properties of respiratory secretions: relationship to mucis transport. In: Baum GL, Priel Z, Roth V, Liron N, Ostfeld EJ, editors. Cilia, mucus and mucociliary intercations. New York: Marcel Drekker; 1998. pp. 317–24.
    1. Rubin BK. Designing clinical trials to evaluate mucus clearance therapy. Respir Care. 2007;52:1348–1361.
    1. Smith SM, Schroeder K, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in community settings. Cochrane Database Syst Rev. 2014;24(11):CD001831.
    1. Wilkinson M, Sugumar K, Milan SJ, Hart A, Crockett A, Crossingham I. Mucolytics for bronchiectasis. Cochrane Database Syst Rev. 2014;2(5):CD001289.
    1. Pharmacovigilance Risk Assessment Committee (PRAC) Revised assessment report: Ambroxol and bromhexine containing medicinal products. (last Accessed October 2016).
    1. Wark P. Bronchitis (acute) Clin Evid. 2015;7:1508.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅